77 related articles for article (PubMed ID: 24100483)
1. Progression of Fabry cardiomyopathy despite enzyme replacement therapy.
Pieroni M; Camporeale A; Della Bona R; Sabini A; Cosmi D; Magnolfi A; Bolognese L
Circulation; 2013 Oct; 128(15):1687-8. PubMed ID: 24100483
[No Abstract] [Full Text] [Related]
2. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
3. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
4. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
7. Tei index in fabry disease.
Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
[TBL] [Abstract][Full Text] [Related]
8. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
9. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
10. [Fabry disease].
Kantola I; Penttinen M; Nuutila P; Viikari J
Duodecim; 2012; 128(7):729-39. PubMed ID: 22612023
[TBL] [Abstract][Full Text] [Related]
11. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing Fabry disease--delays and difficulties within discordant siblings.
Brady M; Montgomery E; Brennan P; Mohindra R; Sayer JA
QJM; 2015 Jul; 108(7):585-90. PubMed ID: 23378663
[No Abstract] [Full Text] [Related]
13. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
Lobo T; Morgan J; Bjorksten A; Nicholls K; Grigg L; Centra E; Becker G
Intern Med J; 2008 Jun; 38(6):407-14. PubMed ID: 18613897
[TBL] [Abstract][Full Text] [Related]
15. Thyroid function in Fabry disease before and after enzyme replacement therapy.
Faggiano A; Severino R; Ramundo V; Russo R; Vuolo L; Del Prete M; Marciello F; Lombardi G; Cianciaruso B; Colao A; Pisani A
Minerva Endocrinol; 2011 Mar; 36(1):1-5. PubMed ID: 21460782
[TBL] [Abstract][Full Text] [Related]
16. Evaluating enzyme replacement therapy in fabry disease.
Koskenvuo JW; Kantola IM
Arch Intern Med; 2010 Mar; 170(6):573-4; author reply 574. PubMed ID: 20308647
[No Abstract] [Full Text] [Related]
17. Fabry's disease in a female, still an under-recognised disease.
Lynch M; O'Loughlin A; Devaney D; O'Donnell B
Ir Med J; 2013 May; 106(5):158. PubMed ID: 23914586
[No Abstract] [Full Text] [Related]
18. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
19. Fabry Disease: An Uncommon Cause of Renal Failure.
López PD; Andreias L; Astiazarán-Symonds E; Chalabi J
Am J Med; 2017 Sep; 130(9):e389-e390. PubMed ID: 28389313
[No Abstract] [Full Text] [Related]
20. Diagnosis and treatment of the cardiovascular consequences of Fabry disease.
Baig S; Vijapurapu R; Alharbi F; Nordin S; Kozor R; Moon J; Bembi B; Geberhiwot T; Steeds RP
QJM; 2019 Jan; 112(1):3-9. PubMed ID: 29878206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
